Page 36 - Read Online
P. 36

Page 108               Oquendo et al. J Transl Genet Genom 2021;5:89-111  https://dx.doi.org/10.20517/jtgg.2021.04

                    identifies a subset with distinct genotype. Leukemia 2015;29:1177-85.  DOI  PubMed
               24.       Parry M, Rose-Zerilli MJ, Ljungström V, et al. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from
                    Deep Sequencing. Clin Cancer Res 2015;21:4174-83.  DOI  PubMed  PMC
               25.       Arribas AJ, Rinaldi A, Mensah AA, et al. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with
                    different clinical and genetic features. Blood 2015;125:1922-31.  DOI  PubMed  PMC
               26.       Arribas AJ, Bertoni F. Methylation patterns in marginal zone lymphoma. Best Pract Res Clin Haematol 2017;30:24-31.  DOI
                    PubMed
               27.       Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of
                    chronic lymphocytic leukemia. Blood 1999;94:1848-54.  PubMed
               28.       Damle RN, Wasil T, Fais F, et al. Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic
                    Lymphocytic Leukemia. Blood 1999;94:1840-7.  PubMed
               29.       Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific
                    lesions with an impact on the clinical outcome. Blood 2011;117:1595-604.  DOI  PubMed
               30.       Arcaini L, Zibellini S, Passamonti F, et al. Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain
                    repertoires. Blood Cells Mol Dis 2009;42:286-91.  DOI  PubMed
               31.       Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell
                    lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010;116:1479-88.  DOI  PubMed
               32.       Rossi D, Deaglio S, Dominguez-Sola D, et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone
                    lymphoma. Blood 2011;118:4930-4.  DOI  PubMed
               33.       Piva R, Deaglio S, Famà R, et al. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone
                    lymphoma. Leukemia 2015;29:503-7.  DOI  PubMed
               34.       Davoli T, Xu AW, Mengwasser KE, et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape
                    the cancer genome. Cell 2013;155:948-62.  DOI  PubMed  PMC
               35.       Sack LM, Davoli T, Li MZ, et al. Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns.
                    Cell 2018;173:499-514.e23.  DOI  PubMed  PMC
               36.       Watkins AJ, Huang Y, Ye H, et al. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis. J
                    Pathol 2010;220:461-74.  DOI  PubMed
               37.       Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines
                    a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002;99:1299-304.  DOI  PubMed
               38.       Fresquet V, Robles EF, Parker A, et al. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a
                    potential tumour suppressor in splenic marginal-zone lymphoma. Br J Haematol 2012;158:712-26.  DOI  PubMed
               39.       Hosono N, Makishima H, Mahfouz R, et al. Recurrent genetic defects on chromosome 5q in myeloid neoplasms. Oncotarget
                    2017;8:6483-95.  DOI  PubMed  PMC
               40.       Venugopal S, Mascarenhas J, Steensma DP. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical
                    consequences. Blood Rev 2021;46:100735.  DOI  PubMed
               41.       Dierlamm J, Rosenberg C, Stul M, et al. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma
                    detected by comparative genomic hybridization. Leukemia 1997;11:747-58.  DOI  PubMed
               42.       Dierlamm J, Michaux L, Wlodarska I, et al. Trisomy 3 in marginal zone B-cell lymphoma: a study based on cytogenetic analysis and
                    fluorescence in situ hybridization. Br J Haematol 1996;93:242-9.  DOI  PubMed
               43.       Hernández JM, García JL, Gutiérrez NC, et al. Novel genomic imbalances in B-Cell splenic marginal zone lymphomas revealed by
                    comparative genomic hybridization and cytogenetics. Am J Pathol 2001;158:1843-50.  DOI  PubMed  PMC
               44.       Solé F, Woessner S, Florensa L, et al. Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone B-cell
                    lymphoma. Br J Haematol 1997;98:446-9.  DOI  PubMed
               45.       Troussard X, Mauvieux L, Radford-Weiss I, et al. Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Français
                    d'Hématologie Cellulaire (GFHC) study. Br J Haematol 1998;101:712-21.  DOI  PubMed
               46.       Robledo C, García JL, Benito R, et al. Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas. PLoS
                    One 2011;6:e24939.  DOI  PubMed  PMC
               47.       Gailllard B, Cornillet-Lefebvre P, Le QH, et al; Groupe Francophone de Cytogénétique Hématologique. Clinical and biological
                    features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas
                    displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities. Br J Haematol 2021;193:72-82.  DOI  PubMed
               48.       Hoang PH, Dobbins SE, Cornish AJ, et al. Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted
                    somatically through multiple mechanisms. Leukemia 2018;32:2459-70.  DOI  PubMed  PMC
               49.       Burns A, Alsolami R, Becq J, et al. Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the
                    mutational landscape between IgHVmut and IgHVunmut subgroups. Leukemia 2018;32:332-42.  DOI  PubMed  PMC
               50.       Arthur SE, Jiang A, Grande BM, et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat
                    Commun 2018;9:4001.  DOI  PubMed  PMC
               51.       Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in
                    chronic lymphocytic leukemia. Nat Genet 2011;44:47-52.  DOI  PubMed
               52.       Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
                    Nature 2011;475:101-5.  DOI  PubMed  PMC
               53.       Oquendo C, Parker H, Oscier D, Ennis S, Gibson J, Strefford JC. Systematic Review of Somatic Mutations in Splenic Marginal Zone
   31   32   33   34   35   36   37   38   39   40   41